Moderna announced phase 3 COVE study of mRNA vaccine against COVID-19 (mRNA-1273) began
On Jul. 27, 2020, Moderna announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against…
Moderna announced expansion of BARDA agreement to support larger phase 3 program for vaccine (mRNA-1273) against COVID-19
On Jul. 26, 2020, Moderna announced a modification to its contract with the Biomedical Advanced Research and Development…
Experimental Coronavirus vaccine is safe and produced immune response
On Jul. 21, 2020, National Institutes of Health (NIH) researchers reported early results from the first COVID-19 vaccine…
GSK and CureVac announced strategic mRNA technology collaboration
On Jul. 21, 2020, GlaxoSmithKline and CureVac announced a strategic collaboration agreement for the research, development, manufacturing and…
Experimental coronavirus vaccine reported safe and produces immune response
On Jul. 21, 2020, researchers from the National Institutes of Health (NIH) announced that early results from the…
Pfizer and BioNTech announced sgreement with the UK for 30 million doses of mRNA-based vaccine candidate against SARS-CoV-2
On Jul. 20, 2020, Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million…
Pfizer and BioNTech announced early positive update from German phase 1/2 COVID-19 vaccine study
On Jul. 20, 2020, BioNTech and Pfizer announced initial data from their ongoing German Phase 1/2, open-label, non-randomized,…
HDT BIOﾒs COVID-19 vaccine candidate HDT-301 induced neutralizing antibody responses after single injection
On Jul. 20, 2020, scientists at HDT Bio, PAI Life Sciences, and the University of Washington announced they…
Placenta lacks major molecules used by SARS-CoV-2 virus to cause infection
On Jul. 14, 2020, a study by NIH researchers reported the placental membranes that contain the fetus and…
Experimental COVID-19 vaccine safe, generated immune response
On Jul. 14, 2020, an investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus…
Moderna announced publication in The New England Journal of Medicine of interim results from phase 1 study of its mRNA vaccine against COVID-19
On Jul. 14, 2020, Moderna announced the publication of an interim analysis of the open-label Phase 1 study…
Pfizer and BioNTech granted FDA Fast Track Designation for two investigational mRNA-based vaccine candidates against SARS-CoV-2
On Jul. 13, 2020, Pfizer and BioNTech announced that two of the companiesﾒ four investigational vaccine candidates from…
Moderna and ROVI announced collaboration for OUS fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate
On Jul. 9, 2020 Moderna and Laboratorios Farmaceuticos Rovi announced a collaboration for large-scale, commercial fill-finish manufacturing of…
Moderna completed enrollment of phase 2 study of its mRNA vaccine against COVID-19 (mRNA-1273)
On Jul. 8, 2020, Moderna announced that it had completed enrollment for both cohorts of the Phase 2…
Pfizer and BioNTech announced early positive data from ongoing phase 1/2 study of mRNA-based vaccine candidate against SARS-CoV-2
On Jul. 1, 2020, Pfizer and BioNTech announced preliminary data from the most advanced of four investigational vaccine…
Moderna and Catalent announced collaboration for fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate
On Jun. 25, 2020 Moderna announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine…
Sanofi and Translate Bio expanded collaboration and license agreement to develop mRNA vaccines for infectious diseases
On Jun. 23, 2020, Sanofi and Translate Bio announced they had agreed to expand their existing 2018 collaboration…
NanoString announced new products to advance COVID-19 disease research
On Jun. 16, 2020, NanoString Technologies announced the availability of new solutions to study the immune response in…
German Federal Government invested 300 million Euros in CureVac
On Jun. 15, 2020, the German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp,…
Cue Health received FDA EUA for Its rapid, portable, molecular point-of-care COVID-19 test
On Jun. 12, 2020, Cue Health announced that it had received Emergency Use Authorization from the U.S. Food…
Moderna advanced late-stage development of vaccine (mRNA-1273) against COVID-19
On Jun. 11, 2020, Moderna announced progress on late-stage development of mRNA-1273, the Company’s mRNA vaccine candidate against…
BioCryst’s galidesivir stops Zika viral replication in primate model
On Jun. 11, 2020, BioCryst Pharmaceuticals announced new data published in Science Translational Medicine that show, in a…
The FDA authorized first next generation sequence test for diagnosing COVID-19
On Jun. 10, 2020, the FDA issued an emergency use authorization (EUA) to Illumina for the first COVID-19…
Moderna announced first participants in each age cohort dosed in phase 2 study of mRNA vaccine against novel Coronavirus
On May 29, 2020, Moderna announced the first participants in each age cohort had been dosed in the…
Mammoth Biosciences collaborated with GSK to develop COVID-19 test using CRISPR-based platform
On May 20, 2020, Mammoth Biosciences announced a collaboration with GSK Consumer Healthcare to develop an accurate, easy-to-use,…
Moderna announced positive interim phase 1 data for mRNA Vaccine against novel Coronavirus
On May 18, 2020, Moderna announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus…
The Jackson Laboratory provided widescale COVID-19 testing in Connecticut
On May 12, 2020, the Jackson Laboratory (JAX), in partnership with the State of Connecticut, announced that it…
Moderna received FDA Fast Track Designation for mRNA vaccine (mRNA-1273) against novel Coronavirus
On May 12, 2020, Moderna announced the U.S. Food and Drug Administration (FDA had granted Fast Track designation…
Arbutus Biopharma announced research initiative to identify novel antiviral therapies for treatment of Coronavirus infections
On May 11, 2020, Arbutus Biopharma announced the establishment of a new research initiative focused on the identification…
OPTI Medical Systems received FDA Emergency Use Authorization for OPTI SARS-CoV-2 RNA PCR test kit for detection of Virus causing COVID-19
On May 7, 2020, OPTI Medical Systems, an IDEXX Laboratories subsidiary announced the U.S. Food and Drug Administration…